Jonathan Zalevsky

“I'd like to spend a few minutes talking about the biology of RESPEC, and specifically the biomarker data we presented at EADB, which provide important new insights into how RESPEC works and help us better understand the clinical responses we've observed.”

“Switching gears, I'll be talking about the biomarker sub-study we conducted in the Phase IIb Resolve AD study in patients with moderate to severe atopic dermatitis.”

“As Howard said over the past year, our clinical data generated from the Resolve AD and Resolve AA studies have confirmed that our approach with RESPEG to stimulate regulatory T-cells translates into a differentiated clinical profile, compelling efficacy, a favorable safety profile, extended dosing frequency, and…”

“I think it's one of the components and approaches medically that we've really taken and, you know, and really defines, you know, our pipeline and it defines our work.”

“Let’s begin today with REZPEG, which is the most advanced IL-2 based T reg mechanism in the field.”